pioglitazone has been researched along with Complications of Diabetes Mellitus in 55 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A total of 522 patients with hypertension and/or dyslipidemia who had one or more silent cerebral infarcts, advanced carotid atherosclerosis or microalbuminuria at baseline were randomly treated with (n=254) or without pioglitazone (n=268) and observed for a medium of 672 days." | 9.19 | Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study. ( Kawamori, R; Kitagawa, K; Kitakaze, M; Matsuhisa, M; Matsumoto, M; Onuma, T; Watada, H; Yamasaki, Y; Yamazaki, T; Yoshii, H, 2014) |
| "This study aimed to explore the effects of pioglitazone treatment on progression from persistent atrial fibrillation (AF) to permanent atrial fibrillation in diabetes mellitus (DM) patients and to investigate the possible mechanisms involved in those effects." | 9.19 | Beneficial effects of pioglitazone on retardation of persistent atrial fibrillation progression in diabetes mellitus patients. ( Liu, B; Wang, G; Wang, J, 2014) |
| "To evaluate the efficacy and safety of combination therapy with candesartan cilexetil (CC) and pioglitazone hydrochloride (PIO) in patients with hypertension and type 2 diabetes mellitus." | 9.15 | Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus. ( Enya, K; Kaku, K; Sugiura, K; Totsuka, N, 2011) |
| "This study investigated the effects of pioglitazone (PIO), ramipril (RAM), or their combination (PIRA) on low-grade inflammation in nondiabetic hypertensive patients with increased cardiovascular risk." | 9.15 | Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study. ( Dekordi, LA; Forst, T; Fuchs, W; Hanefeld, M; Kleine, I; Müller, J; Pfützner, A, 2011) |
| "This study examined whether pioglitazone, an agonist of peroxisome proliferator-activated receptor gamma, may stabilize vulnerable plaque with use of ultrasound evaluation of carotid artery plaque echolucency in patients with acute coronary syndrome (ACS) and type 2 diabetes mellitus (DM)." | 9.14 | Rapid improvement of carotid plaque echogenicity within 1 month of pioglitazone treatment in patients with acute coronary syndrome. ( Fujioka, D; Hirano, M; Kawabata, K; Kitta, Y; Kobayashi, T; Kodama, Y; Kugiyama, K; Nakamura, K; Nakamura, T; Obata, JE; Saito, Y; Sano, K; Yano, T, 2009) |
| "This article reviews human observations on pioglitazone and bladder cancer risk." | 8.88 | Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities? ( Tseng, CH, 2012) |
| "The aim of the study was to empirically demonstrate the effect of varying study designs when evaluating the safety of pioglitazone in treating bladder cancer." | 7.91 | Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes. ( Buse, JB; Garry, EM; Gokhale, M; Lund, JL; Nielsen, ME; Pate, V; Stürmer, T, 2019) |
| " This study aimed to determine the effects of a PPAR-g agonist pioglitazone on atherogenesis in an ApoE knockout mouse (ApoE-/-) diabetic mouse model and in a cultured vascular smooth muscle cells (VSMCs) model." | 7.85 | Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling. ( Di, B; Gao, H; Li, H; Li, W; Shen, X, 2017) |
| "Rosiglitazone was found associated with approximately a 43% increase in risk of acute myocardial infarction (AMI) in a two meta-analyses of clinical trials." | 7.75 | Rosiglitazone and myocardial infarction in patients previously prescribed metformin. ( Bassett, K; Carney, G; Dormuth, CR; Maclure, M; Schneeweiss, S; Wright, JM, 2009) |
| "Very recent subgroup analysis from the PROspective pioglitAzone Clinical Trial In macroVascular Events has shown that pioglitazone reduces the risk of recurrent stroke in type 2 diabetic patients." | 7.74 | Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2007) |
| " Nevertheless, pioglitazone (when compared to rosiglitazone) was found to have long-term value as a treatment option for T2DM patients with dyslipidemia treated within the US payer setting." | 7.74 | Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US. ( Baran, RW; Minshall, ME; Pandya, BJ; St Charles, M; Tunis, SL, 2008) |
| " Pioglitazone is an oral antidiabetic agent that acts primarily on adipose tissue to reduce insulin resistance." | 7.72 | Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report. ( Bunnag, P; Prasithsirikul, W, 2004) |
| "Pioglitazone (PIO) is a new class of anti-diabetic agent with an anti-inflammatory effect." | 6.76 | Effect of pretreatment with pioglitazone on reperfusion injury in diabetic patients with acute myocardial infarction. ( Abe, M; Kasahara, Y; Kataoka, Y; Kokubu, N; Otsuka, Y; Yagi, N, 2011) |
| "Pioglitazone was also found to increase significantly the apo A1 levels in patients with hyperinsulinemia, but there was no significant increase in patients given both atorvastatin and pioglitazone." | 6.73 | Effect of pioglitazone and its combination with statins in coronary artery disease patients with hyperinsulinemia. ( Baxi, H; Chag, M; Chandarana, A; Goyal, R; Mehta, A; Naik, A; Parikh, K; Shah, K; Shah, U, 2007) |
| "Pioglitazone treatment in non-diabetic patients with CAD was associated with a significantly better coronary endothelial function compared to placebo." | 6.73 | Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease. ( Höher, M; Hombach, V; Kestler, HA; Koenig, W; Marx, N; Nusser, T; Wöhrle, J, 2008) |
| "Metformin-glinides was most cost-effective in the base-case analysis; Metformin-glinides saved $194 USD for one percentage point of reduction in CVD risk, as compared to Metformin-SU." | 5.43 | Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan. ( Chen, YT; Liu, YM; Ou, HT; Wu, JS, 2016) |
| " A total of 522 patients with hypertension and/or dyslipidemia who had one or more silent cerebral infarcts, advanced carotid atherosclerosis or microalbuminuria at baseline were randomly treated with (n=254) or without pioglitazone (n=268) and observed for a medium of 672 days." | 5.19 | Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study. ( Kawamori, R; Kitagawa, K; Kitakaze, M; Matsuhisa, M; Matsumoto, M; Onuma, T; Watada, H; Yamasaki, Y; Yamazaki, T; Yoshii, H, 2014) |
| "This study aimed to explore the effects of pioglitazone treatment on progression from persistent atrial fibrillation (AF) to permanent atrial fibrillation in diabetes mellitus (DM) patients and to investigate the possible mechanisms involved in those effects." | 5.19 | Beneficial effects of pioglitazone on retardation of persistent atrial fibrillation progression in diabetes mellitus patients. ( Liu, B; Wang, G; Wang, J, 2014) |
| "To evaluate the efficacy and safety of combination therapy with candesartan cilexetil (CC) and pioglitazone hydrochloride (PIO) in patients with hypertension and type 2 diabetes mellitus." | 5.15 | Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus. ( Enya, K; Kaku, K; Sugiura, K; Totsuka, N, 2011) |
| "This study investigated the effects of pioglitazone (PIO), ramipril (RAM), or their combination (PIRA) on low-grade inflammation in nondiabetic hypertensive patients with increased cardiovascular risk." | 5.15 | Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study. ( Dekordi, LA; Forst, T; Fuchs, W; Hanefeld, M; Kleine, I; Müller, J; Pfützner, A, 2011) |
| "In T2DM patients, pioglitazone was associated with improvement in some measures of left ventricular diastolic function, myocardial glucose uptake, and whole-body insulin sensitivity." | 5.14 | Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. ( Bax, JJ; de Jong, HW; de Roos, A; Diamant, M; Heine, RJ; Kamp, O; Lamb, HJ; Lammertsma, AA; Lubberink, M; Paulus, WJ; Rijzewijk, LJ; Romijn, JA; Smit, JW; van der Meer, RW, 2009) |
| "This study examined whether pioglitazone, an agonist of peroxisome proliferator-activated receptor gamma, may stabilize vulnerable plaque with use of ultrasound evaluation of carotid artery plaque echolucency in patients with acute coronary syndrome (ACS) and type 2 diabetes mellitus (DM)." | 5.14 | Rapid improvement of carotid plaque echogenicity within 1 month of pioglitazone treatment in patients with acute coronary syndrome. ( Fujioka, D; Hirano, M; Kawabata, K; Kitta, Y; Kobayashi, T; Kodama, Y; Kugiyama, K; Nakamura, K; Nakamura, T; Obata, JE; Saito, Y; Sano, K; Yano, T, 2009) |
| "This article reviews human observations on pioglitazone and bladder cancer risk." | 4.88 | Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities? ( Tseng, CH, 2012) |
| " 3041 were excluded, and we did a systematic review and meta-analysis of the seven remaining randomised double-blind clinical trials of drug-related congestive heart failure in patients given TZDs (either rosiglitazone or pioglitazone)." | 4.84 | Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. ( Lago, RM; Nesto, RW; Singh, PP, 2007) |
| "The aim of the study was to empirically demonstrate the effect of varying study designs when evaluating the safety of pioglitazone in treating bladder cancer." | 3.91 | Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes. ( Buse, JB; Garry, EM; Gokhale, M; Lund, JL; Nielsen, ME; Pate, V; Stürmer, T, 2019) |
| " This study aimed to determine the effects of a PPAR-g agonist pioglitazone on atherogenesis in an ApoE knockout mouse (ApoE-/-) diabetic mouse model and in a cultured vascular smooth muscle cells (VSMCs) model." | 3.85 | Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling. ( Di, B; Gao, H; Li, H; Li, W; Shen, X, 2017) |
| " Treatment with pioglitazone improved heart function by decreasing the expression of AGEs and OX-62 in the rats with myocardial infarction (MI) plus diabetes." | 3.80 | Advanced glycation end products promote heart failure through inducing the immune maturation of dendritic cells. ( Cao, W; Chen, J; Chen, X; Chen, Y; Liu, P, 2014) |
| " In this study, we aim to develop a drug-eluting scaffold with a payload of pioglitazone to simultaneously rein in hyperglycemia and recoup lost renal functions in diabetic mice that underwent islet transplantation." | 3.80 | A synergistic therapeutic scheme for hyperglycemia and nephrotic disorders in diabetes. ( Fu, Z; Han, B; He, Q; Tang, K; Xu, J; Yin, H; Zhang, X, 2014) |
| "Administration of rutin (50 and 100 mg/kg) and pioglitazone (10 mg/kg) orally for 3 weeks treatment significantly improved body weight, reduced plasma glucose and glycosylated hemoglobin, pro-inflammatory cytokines (IL-6 and TNF-alpha), restored the depleted liver antioxidant status and serum lipid profile in high fat diet + streptozotocin induced type 2 diabetic rats." | 3.80 | Anti-hyperglycemic activity of rutin in streptozotocin-induced diabetic rats: an effect mediated through cytokines, antioxidants and lipid biomarkers. ( Ansari, AA; Naik, SR; Niture, NT, 2014) |
| "Higher risks for death (overall and due to cardiovascular disease) and heart failure were found for rosiglitazone compared to pioglitazone." | 3.77 | Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data. ( Gallagher, AM; Leufkens, HG; Seabroke, S; Smeeth, L; van Staa, TP, 2011) |
| " This utilized a single daily dose of pioglitazone for pediatric patients with severe sepsis and septic shock based upon adult and minimal adolescent data." | 3.77 | Optimal study design for pioglitazone in septic pediatric patients. ( Ding, L; Kaplan, J; Sherwin, CM; Spigarelli, MG; Vinks, AA, 2011) |
| "Rosiglitazone was found associated with approximately a 43% increase in risk of acute myocardial infarction (AMI) in a two meta-analyses of clinical trials." | 3.75 | Rosiglitazone and myocardial infarction in patients previously prescribed metformin. ( Bassett, K; Carney, G; Dormuth, CR; Maclure, M; Schneeweiss, S; Wright, JM, 2009) |
| "Our findings from a large population-based cohort of US seniors are compatible with an increased risk of all-cause mortality and congestive heart failure in patients initiating therapy with rosiglitazone compared with similar patients initiating therapy with pioglitazone." | 3.74 | Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. ( Levin, R; Setoguchi, S; Solomon, DH; Winkelmayer, WC, 2008) |
| " Nevertheless, pioglitazone (when compared to rosiglitazone) was found to have long-term value as a treatment option for T2DM patients with dyslipidemia treated within the US payer setting." | 3.74 | Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US. ( Baran, RW; Minshall, ME; Pandya, BJ; St Charles, M; Tunis, SL, 2008) |
| "Very recent subgroup analysis from the PROspective pioglitAzone Clinical Trial In macroVascular Events has shown that pioglitazone reduces the risk of recurrent stroke in type 2 diabetic patients." | 3.74 | Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2007) |
| "To determine whether thiazolidinediones cause significant changes in intravascular volume, anemia, or chronic heart failure; to determine which thiazolidinedione, rosiglitazone or pioglitazone, has a greater propensity to cause these adverse effects; and to evaluate thiazolidinedione efficacy in patients with diabetes mellitus and end-stage renal disease who require hemodialysis." | 3.72 | Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. ( Allcock, NM; Manley, HJ, 2003) |
| " Pioglitazone is an oral antidiabetic agent that acts primarily on adipose tissue to reduce insulin resistance." | 3.72 | Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report. ( Bunnag, P; Prasithsirikul, W, 2004) |
| "Pioglitazone (PIO) is a new class of anti-diabetic agent with an anti-inflammatory effect." | 2.76 | Effect of pretreatment with pioglitazone on reperfusion injury in diabetic patients with acute myocardial infarction. ( Abe, M; Kasahara, Y; Kataoka, Y; Kokubu, N; Otsuka, Y; Yagi, N, 2011) |
| "Pioglitazone treatment in non-diabetic patients with CAD was associated with a significantly better coronary endothelial function compared to placebo." | 2.73 | Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease. ( Höher, M; Hombach, V; Kestler, HA; Koenig, W; Marx, N; Nusser, T; Wöhrle, J, 2008) |
| "Pioglitazone was also found to increase significantly the apo A1 levels in patients with hyperinsulinemia, but there was no significant increase in patients given both atorvastatin and pioglitazone." | 2.73 | Effect of pioglitazone and its combination with statins in coronary artery disease patients with hyperinsulinemia. ( Baxi, H; Chag, M; Chandarana, A; Goyal, R; Mehta, A; Naik, A; Parikh, K; Shah, K; Shah, U, 2007) |
| "Though gout is more prevalent in men than women, it remains unclear whether gender influences risk factors for incident gout." | 2.61 | Gender-specific risk factors for gout: a systematic review of cohort studies. ( Belcher, J; Evans, PL; Hay, CA; Mallen, CD; Prior, JA; Roddy, E, 2019) |
| "The association between nonalcoholic steatohepatitis and cardiovascular disease is clear, though causality remains to be proven in well-controlled prospective studies." | 2.52 | Nonalcoholic fatty liver disease: a systematic review. ( Rinella, ME, 2015) |
| "Although a correlation between pancreatic cancer and diabetes mellitus has long been suspected, the potential role diabetes mellitus plays in the pathogenicity of both hepatocellular carcinoma and colon cancer is becoming increasingly well defined." | 2.50 | Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. ( Herrigel, DJ; Moss, RA, 2014) |
| "Patients with type 2 diabetes mellitus frequently have coexistent dyslipidemia, hypertension, and obesity, and are at risk for microvascular and macrovascular disease complications such as myocardial infarction, stroke, retinopathy, and microalbuminuria." | 2.42 | Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. ( Chilton, RJ; Stolar, MW, 2003) |
| "Metformin-glinides was most cost-effective in the base-case analysis; Metformin-glinides saved $194 USD for one percentage point of reduction in CVD risk, as compared to Metformin-SU." | 1.43 | Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan. ( Chen, YT; Liu, YM; Ou, HT; Wu, JS, 2016) |
| "Pioglitazone was markedly effective in glycemic control in this case." | 1.35 | Clinical characteristics and efficacy of pioglitazone in a Japanese diabetic patient with an unusual type of familial partial lipodystrophy. ( Chen, W; Ebihara, K; Hosoda, K; Ito, J; Iwanishi, M; Kusakabe, T; Masuzaki, H; Nakao, K, 2009) |
| "Pioglitazone failed to increase adiponectin secretion from either ND or T2D VAT and increased cellular content only in ND VAT." | 1.35 | Adiponectin secretion and response to pioglitazone is depot dependent in cultured human adipose tissue. ( Ciaraldi, TP; Henry, RR; Oh, DK; Phillips, SA; Savu, MK, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 30 (54.55) | 29.6817 |
| 2010's | 24 (43.64) | 24.3611 |
| 2020's | 1 (1.82) | 2.80 |
| Authors | Studies |
|---|---|
| Lian, J | 1 |
| Fu, J | 1 |
| Yamada, T | 1 |
| Hiraoka, E | 1 |
| Miyazaki, T | 1 |
| Sato, J | 1 |
| Ban, N | 1 |
| Gao, H | 1 |
| Li, H | 1 |
| Li, W | 1 |
| Shen, X | 1 |
| Di, B | 1 |
| Garry, EM | 1 |
| Buse, JB | 1 |
| Gokhale, M | 1 |
| Lund, JL | 1 |
| Nielsen, ME | 1 |
| Pate, V | 1 |
| Stürmer, T | 1 |
| Evans, PL | 1 |
| Prior, JA | 1 |
| Belcher, J | 1 |
| Hay, CA | 1 |
| Mallen, CD | 1 |
| Roddy, E | 1 |
| Yoshii, H | 1 |
| Onuma, T | 1 |
| Yamazaki, T | 1 |
| Watada, H | 1 |
| Matsuhisa, M | 1 |
| Matsumoto, M | 1 |
| Kitagawa, K | 2 |
| Kitakaze, M | 1 |
| Yamasaki, Y | 2 |
| Kawamori, R | 2 |
| Cao, W | 1 |
| Chen, J | 1 |
| Chen, Y | 1 |
| Chen, X | 1 |
| Liu, P | 1 |
| He, Q | 1 |
| Zhang, X | 1 |
| Han, B | 1 |
| Xu, J | 1 |
| Tang, K | 1 |
| Fu, Z | 1 |
| Yin, H | 1 |
| Zhang, J | 1 |
| Huang, X | 1 |
| Wang, L | 1 |
| Niture, NT | 1 |
| Ansari, AA | 1 |
| Naik, SR | 1 |
| Liu, B | 1 |
| Wang, J | 1 |
| Wang, G | 1 |
| Herrigel, DJ | 1 |
| Moss, RA | 1 |
| Rinella, ME | 1 |
| Kado, T | 1 |
| Usui, I | 1 |
| Tobe, K | 1 |
| Ou, HT | 1 |
| Chen, YT | 1 |
| Liu, YM | 1 |
| Wu, JS | 1 |
| Dormandy, JA | 1 |
| Betteridge, DJ | 1 |
| Schernthaner, G | 1 |
| Pirags, V | 1 |
| Norgren, L | 1 |
| Phillips, SA | 1 |
| Ciaraldi, TP | 1 |
| Oh, DK | 1 |
| Savu, MK | 1 |
| Henry, RR | 1 |
| Hirano, M | 1 |
| Nakamura, T | 2 |
| Kitta, Y | 1 |
| Yano, T | 1 |
| Kobayashi, T | 1 |
| Sano, K | 1 |
| Fujioka, D | 1 |
| Saito, Y | 1 |
| Kodama, Y | 1 |
| Kawabata, K | 1 |
| Nakamura, K | 1 |
| Obata, JE | 1 |
| Kugiyama, K | 1 |
| Tunis, SL | 2 |
| Minshall, ME | 2 |
| St Charles, M | 2 |
| Pandya, BJ | 2 |
| Baran, RW | 2 |
| Sano, H | 1 |
| Tajima, N | 1 |
| Winkelmayer, WC | 1 |
| Setoguchi, S | 1 |
| Levin, R | 1 |
| Solomon, DH | 1 |
| Aoyama, T | 1 |
| Ikejima, K | 1 |
| Kon, K | 1 |
| Okumura, K | 1 |
| Arai, K | 1 |
| Watanabe, S | 1 |
| van der Meer, RW | 1 |
| Rijzewijk, LJ | 1 |
| de Jong, HW | 1 |
| Lamb, HJ | 1 |
| Lubberink, M | 1 |
| Romijn, JA | 1 |
| Bax, JJ | 1 |
| de Roos, A | 1 |
| Kamp, O | 1 |
| Paulus, WJ | 1 |
| Heine, RJ | 2 |
| Lammertsma, AA | 1 |
| Smit, JW | 1 |
| Diamant, M | 1 |
| Gropler, RJ | 1 |
| Dormuth, CR | 1 |
| Maclure, M | 1 |
| Carney, G | 1 |
| Schneeweiss, S | 1 |
| Bassett, K | 1 |
| Wright, JM | 1 |
| Iwanishi, M | 1 |
| Ebihara, K | 1 |
| Kusakabe, T | 1 |
| Chen, W | 1 |
| Ito, J | 1 |
| Masuzaki, H | 1 |
| Hosoda, K | 1 |
| Nakao, K | 1 |
| Katakami, N | 1 |
| Furukado, S | 1 |
| Nagatsuka, K | 1 |
| Kashiwagi, A | 1 |
| Daida, H | 1 |
| Kaku, K | 2 |
| Kurra, S | 1 |
| Siris, E | 1 |
| Sherwin, CM | 1 |
| Ding, L | 1 |
| Kaplan, J | 1 |
| Spigarelli, MG | 1 |
| Vinks, AA | 1 |
| Kataoka, Y | 1 |
| Yagi, N | 1 |
| Kokubu, N | 1 |
| Kasahara, Y | 1 |
| Abe, M | 1 |
| Otsuka, Y | 1 |
| Pfützner, A | 1 |
| Hanefeld, M | 1 |
| Dekordi, LA | 1 |
| Müller, J | 1 |
| Kleine, I | 1 |
| Fuchs, W | 1 |
| Forst, T | 1 |
| Shinohara, Y | 1 |
| Enya, K | 1 |
| Sugiura, K | 1 |
| Totsuka, N | 1 |
| Gallagher, AM | 1 |
| Smeeth, L | 1 |
| Seabroke, S | 1 |
| Leufkens, HG | 1 |
| van Staa, TP | 1 |
| Tseng, CH | 1 |
| Yokoi, H | 1 |
| Suzuki, M | 1 |
| Odaka, H | 1 |
| Manley, HJ | 1 |
| Allcock, NM | 1 |
| Stolar, MW | 1 |
| Chilton, RJ | 1 |
| Prasithsirikul, W | 1 |
| Bunnag, P | 1 |
| Fonseca, V | 1 |
| Jawa, A | 1 |
| Asnani, S | 1 |
| Irons, BK | 1 |
| Greene, RS | 1 |
| Mazzolini, TA | 1 |
| Edwards, KL | 1 |
| Sleeper, RB | 1 |
| Holleman, F | 1 |
| Gerdes, VE | 1 |
| de Vries, JH | 1 |
| Hoekstra, JB | 1 |
| Veneman, TF | 1 |
| Schmitz, OE | 1 |
| Brock, B | 1 |
| Rungby, J | 1 |
| Madsbad, S | 1 |
| Pathan, AR | 1 |
| Viswanad, B | 1 |
| Sonkusare, SK | 1 |
| Ramarao, P | 1 |
| Kusuyama, T | 1 |
| Omura, T | 1 |
| Nishiya, D | 1 |
| Enomoto, S | 1 |
| Matsumoto, R | 1 |
| Takeuchi, K | 1 |
| Yoshikawa, J | 1 |
| Yoshiyama, M | 1 |
| Mehta, A | 1 |
| Shah, U | 1 |
| Parikh, K | 1 |
| Chag, M | 1 |
| Baxi, H | 1 |
| Chandarana, A | 1 |
| Naik, A | 2 |
| Shah, K | 1 |
| Goyal, R | 1 |
| Yamamoto, E | 1 |
| Kataoka, K | 1 |
| Yamashita, T | 1 |
| Tokutomi, Y | 1 |
| Dong, YF | 1 |
| Matsuba, S | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Lago, RM | 1 |
| Singh, PP | 1 |
| Nesto, RW | 1 |
| Wöhrle, J | 1 |
| Marx, N | 1 |
| Koenig, W | 1 |
| Hombach, V | 1 |
| Kestler, HA | 1 |
| Höher, M | 1 |
| Nusser, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Combination Therapy With Dapagliflozin Plus Low Dose Pioglitazone on Hospitalization Rate in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction[NCT03794518] | Phase 3 | 648 participants (Anticipated) | Interventional | 2019-03-31 | Not yet recruiting | ||
| The Role of Microbiome Reprogramming on Liver Fat Accumulation[NCT03914495] | 57 participants (Actual) | Interventional | 2019-05-21 | Terminated (stopped due to PI carefully considered multiple factors and decided to close study to any further enrollment.) | |||
| Metabolic Surgery for the Treatment and Understanding of Non-Alcoholic Steato-Hepatitis (NASH): Weight-Dependent and Weight-Independent Effects[NCT04282005] | 28 participants (Anticipated) | Interventional | 2020-02-13 | Recruiting | |||
| Predictors of Improvement of Nonalcoholic Fatty Liver Disease in Morbidly Obese Patients Undergoing Bariatric Surgery[NCT04059029] | 200 participants (Anticipated) | Observational | 2016-10-31 | Enrolling by invitation | |||
| Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet[NCT03141008] | 54 participants (Actual) | Observational | 2017-09-15 | Completed | |||
| PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy[NCT00174993] | Phase 3 | 4,373 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus[NCT01761318] | Phase 4 | 50 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Pharmacokinetic Characteristics of Pioglitazone and Preliminary Biomarker Response in Adolescents Aged 12 to 17 Years With Severe Sepsis and Septic Shock[NCT01352182] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
We examined the effect of pioglitazone Area under the curve on IL-6 in patients receiving pioglitazone only. (Control subjects did not receive pioglitazone). The pharmacokinetic endpoint was area under the curve (AUC) total/days of pioglitazone administration (NCT01352182)
Timeframe: Evaluation of inflammatory biomarkers will be obtained prior to dosing for the first five days of the study
| Intervention | ng/ml (Least Squares Mean) |
|---|---|
| Pioglitazone Hydrochloride | -1.4425 |
| Normal Standard Care | NA |
The number of hypoglycemic events in pioglitazone vs standard care. Hypoglycemia was defined as blood glucose level that remains <40mg/dl despite dextrose bolus treatment. (NCT01352182)
Timeframe: Assessement over five days
| Intervention | events (Number) |
|---|---|
| Pioglitazone Hydrochloride | 0 |
| Normal Standard Care | 0 |
Pioglitazone concentration as the total area under curve divided by the number of days receiving the drug in subjects who took the drug by mouth versus by naso-gastric tube (NCT01352182)
Timeframe: five days
| Intervention | ng*h/ml (Mean) |
|---|---|
| Pioglitazone Hydrochloride by Mouth | 5363 |
| Pioglitazone Hydrochloride by Nasogastric Tube | 1052 |
ALT levels in blood from subject on the final day of enrollment (NCT01352182)
Timeframe: Final day of study
| Intervention | U/L (Median) |
|---|---|
| Pioglitazone Hydrochloride | 21.5 |
| Normal Standard Care | 24.5 |
BUN levels in blood from subject on the final day of enrollment (NCT01352182)
Timeframe: Final day of study
| Intervention | mg/dl (Median) |
|---|---|
| Pioglitazone Hydrochloride | 7.5 |
| Normal Standard Care | 10 |
Creatinine levels in blood from subject on the final day of enrollment (NCT01352182)
Timeframe: Final day of study
| Intervention | mg/dl (Median) |
|---|---|
| Pioglitazone Hydrochloride | 0.72 |
| Normal Standard Care | 0.415 |
12 reviews available for pioglitazone and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Bayes Theorem; Blood Glucose; Body Mass Index; Bo | 2021 |
Gender-specific risk factors for gout: a systematic review of cohort studies.
Topics: Age Factors; Animals; Body Size; Body Weight; Cohort Studies; Diabetes Complications; Diet; Diuretic | 2019 |
Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Diabetes Complications; Humans; Hyp | 2014 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live | 2015 |
[Current evidence-based medicine for early intervention in diabetes].
Topics: Diabetes Complications; Diabetes Mellitus; Diet, Diabetic; Evidence-Based Medicine; Exercise Therapy | 2008 |
[Japanese Guidelines for the Management of Stroke 2009 : important revised points necessary for the neurologist].
Topics: Aspirin; Atorvastatin; Cilostazol; Diabetes Complications; Dyslipidemias; Evidence-Based Medicine; H | 2010 |
Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?
Topics: Bias; Comorbidity; Data Interpretation, Statistical; Diabetes Complications; Epidemiologic Research | 2012 |
[Pioglitazone].
Topics: Angioplasty, Balloon, Coronary; Coronary Restenosis; Diabetes Complications; Humans; Hypoglycemic Ag | 2011 |
[Hypertension and insulin resistance in obese type 2 diabetic Wistar fatty rat].
Topics: Animals; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Models, Anima | 2003 |
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hemod | 2003 |
Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Heart Failure; Humans; H | 2006 |
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heart Failure; H | 2007 |
12 trials available for pioglitazone and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study.
Topics: Aged; Aged, 80 and over; Blood Pressure; Diabetes Complications; Diabetes Mellitus, Type 2; Dyslipid | 2014 |
Beneficial effects of pioglitazone on retardation of persistent atrial fibrillation progression in diabetes mellitus patients.
Topics: Aged; Angiotensin II; Atrial Fibrillation; Diabetes Complications; Disease Progression; Double-Blind | 2014 |
Impact of peripheral arterial disease in patients with diabetes--results from PROactive (PROactive 11).
Topics: Adult; Aged; Diabetes Complications; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; | 2009 |
Rapid improvement of carotid plaque echogenicity within 1 month of pioglitazone treatment in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Calibration; Carotid Stenosis; Diabetes Complications; Diabetes Melli | 2009 |
Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.
Topics: Adenosine Triphosphate; Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combi | 2009 |
Long-term effects of pioglitazone on carotid atherosclerosis in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity.
Topics: Adult; Aged; Asian People; Carotid Arteries; Carotid Artery Diseases; Case-Control Studies; Comorbid | 2010 |
Effect of pretreatment with pioglitazone on reperfusion injury in diabetic patients with acute myocardial infarction.
Topics: Aged; Creatine Kinase; Diabetes Complications; Female; Follow-Up Studies; Humans; Hypoglycemic Agent | 2011 |
Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Blood Vessels; Cardiovascular Diseases; Diabetes C | 2011 |
Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetes Complica | 2011 |
[The place of Glitazones in the treatment of diabetes: after the PROactive study].
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Angiopathies; H | 2006 |
Effect of pioglitazone and its combination with statins in coronary artery disease patients with hyperinsulinemia.
Topics: Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Blood Glucose; Body Mass Index; Cholesterol, HD | 2007 |
Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease.
Topics: Coronary Artery Disease; Diabetes Complications; Double-Blind Method; Endothelium, Vascular; Female; | 2008 |
31 other studies available for pioglitazone and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Diabetes as First Manifestation of Autoimmune Pancreatitis.
Topics: Adrenal Cortex Hormones; Aged; Autoimmune Diseases; Diabetes Complications; Diabetes Mellitus; Dysli | 2017 |
Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cells, Cultured; Diabetes Complications; Diabetes Melli | 2017 |
Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes.
Topics: Aged; Aged, 80 and over; Comparative Effectiveness Research; Diabetes Complications; Diabetes Mellit | 2019 |
Advanced glycation end products promote heart failure through inducing the immune maturation of dendritic cells.
Topics: Animals; Coculture Techniques; Dendritic Cells; Diabetes Complications; Dose-Response Relationship, | 2014 |
A synergistic therapeutic scheme for hyperglycemia and nephrotic disorders in diabetes.
Topics: Animals; Blood Urea Nitrogen; Creatinine; Diabetes Complications; Diabetes Mellitus; Humans; Hypergl | 2014 |
Pioglitazone inhibits the expression of matrix metalloproteinase-9, a protein involved in diabetes-associated wound healing.
Topics: Animals; Cattle; Cell Line; Cell Survival; Diabetes Complications; Gene Expression; Glycation End Pr | 2014 |
Anti-hyperglycemic activity of rutin in streptozotocin-induced diabetic rats: an effect mediated through cytokines, antioxidants and lipid biomarkers.
Topics: Animals; Antioxidants; Biomarkers; Blood Glucose; Body Weight; Diabetes Complications; Diabetes Mell | 2014 |
[Pioglitazone and the risk of bladder cancer].
Topics: Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agents; Pioglitazone; Thiazolidinedi | 2016 |
Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan.
Topics: Acarbose; Aged; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mel | 2016 |
Adiponectin secretion and response to pioglitazone is depot dependent in cultured human adipose tissue.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Adult; Cytokines; Diabetes Complications; Diabetes Mellitus | 2008 |
Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US.
Topics: Aged; Cohort Studies; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Dise | 2008 |
Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.
Topics: Aged; Diabetes Complications; Diabetes Mellitus; Female; Heart Failure; Humans; Hypoglycemic Agents; | 2008 |
Pioglitazone promotes survival and prevents hepatic regeneration failure after partial hepatectomy in obese and diabetic KK-A(y) mice.
Topics: Adipokines; Animals; Blood Glucose; Diabetes Complications; Hepatectomy; Hypoglycemic Agents; Insuli | 2009 |
Lost in translation: modulation of the metabolic-functional relation in the diabetic human heart.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty A | 2009 |
A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
Topics: Aged; Comorbidity; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Co | 2009 |
Rosiglitazone and myocardial infarction in patients previously prescribed metformin.
Topics: Aged; Case-Control Studies; Cohort Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Femal | 2009 |
Clinical characteristics and efficacy of pioglitazone in a Japanese diabetic patient with an unusual type of familial partial lipodystrophy.
Topics: Absorptiometry, Photon; Adiponectin; Adiposity; Blood Glucose; Body Composition; Diabetes Complicati | 2009 |
Diabetes and bone health: the relationship between diabetes and osteoporosis-associated fractures.
Topics: Accidental Falls; Bone and Bones; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellit | 2011 |
Optimal study design for pioglitazone in septic pediatric patients.
Topics: Adolescent; Adult; Child; Child, Preschool; Clinical Trials as Topic; Computer Simulation; Diabetes | 2011 |
Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Databases | 2011 |
Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis.
Topics: Aged; Aged, 80 and over; Blood Pressure; Comorbidity; Diabetes Complications; Diabetes Mellitus; Fem | 2003 |
Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report.
Topics: Diabetes Complications; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Administration Sch | 2004 |
[Type 2 diabetic as cardiovascular risk patient].
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Age | 2005 |
Commentary: the PROactive study--the glass is half full.
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Hum | 2006 |
[Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Evidence-Based Medicine; | 2006 |
[Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Evidence-Based Medicine; | 2006 |
[Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Evidence-Based Medicine; | 2006 |
Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats.
Topics: Administration, Oral; Aging; Animals; Antibiotics, Antineoplastic; Brain Chemistry; Cognition; Demen | 2006 |
Effects of treatment for diabetes mellitus on circulating vascular progenitor cells.
Topics: Actins; Adult; Atherosclerosis; Blood Glucose; Cell Proliferation; Diabetes Complications; Diabetes | 2006 |
[Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].
Topics: Cholesterol, HDL; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Th | 2007 |
Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure.
Topics: Animals; Blood Glucose; Blood Pressure; Cerebral Arteries; Cytokines; Diabetes Complications; Diseas | 2007 |